Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Pharmacosimulation of interruptions and its solution in intravenous administration of cangrelor.

Masyuk M, Heramvand N, Muessig JM, Nia AM, Polzin A, Kollmann M, Kelm M, Jung C.

Clin Hemorheol Microcirc. 2018;68(4):421-425. doi: 10.3233/CH-170323.

PMID:
29036802
2.

Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist.

Akers WS, Oh JJ, Oestreich JH, Ferraris S, Wethington M, Steinhubl SR.

J Clin Pharmacol. 2010 Jan;50(1):27-35. doi: 10.1177/0091270009344986. Epub 2009 Sep 24.

PMID:
19779037
3.

Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.

Greenbaum AB, Grines CL, Bittl JA, Becker RC, Kereiakes DJ, Gilchrist IC, Clegg J, Stankowski JE, Grogan DR, Harrington RA, Emanuelsson H, Weaver WD.

Am Heart J. 2006 Mar;151(3):689.e1-689.e10.

PMID:
16504633
4.

Pharmacodynamic effects during the transition between cangrelor and ticagrelor.

Schneider DJ, Agarwal Z, Seecheran N, Keating FK, Gogo P.

JACC Cardiovasc Interv. 2014 Apr;7(4):435-42. doi: 10.1016/j.jcin.2013.08.017. Epub 2014 Mar 19.

5.

Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.

Ravnefjord A, Weilitz J, Emanuelsson BM, van Giezen JJ.

Thromb Res. 2012 Oct;130(4):622-8. doi: 10.1016/j.thromres.2012.07.021. Epub 2012 Aug 19.

PMID:
22909827
7.

Cangrelor for treatment during percutaneous coronary intervention.

Oestreich JH, Dobesh PP.

Future Cardiol. 2014 Mar;10(2):201-13. doi: 10.2217/fca.13.108.

PMID:
24762247
8.

Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data.

Tamborini Permunian E, Riva N, Guasti L, Squizzato A.

Expert Opin Drug Metab Toxicol. 2015 Apr;11(4):625-37. doi: 10.1517/17425255.2015.1021330. Epub 2015 Mar 1. Review.

PMID:
25728292
9.

Cangrelor for the treatment of patients with Arterial Thrombosis.

Tantry U, Chaudhary R, Kubica J, Bliden K, Gurbel PA.

Expert Opin Pharmacother. 2018 Aug;19(12):1389-1398. doi: 10.1080/14656566.2018.1506767. Epub 2018 Aug 13. Review.

PMID:
30102083
10.

Cangrelor for the management and prevention of arterial thrombosis.

Storey RF, Sinha A.

Expert Rev Cardiovasc Ther. 2016 Sep;14(9):991-9. doi: 10.1080/14779072.2016.1207528. Epub 2016 Jul 8. Review.

11.

Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction.

Mohammad MA, Andell P, Koul S, James S, Scherstén F, Götberg M, Erlinge D.

Platelets. 2017 Jun;28(4):414-416. doi: 10.1080/09537104.2016.1246714. Epub 2016 Nov 25.

PMID:
27885888
12.

Cangrelor: a novel P2Y12 receptor antagonist.

Norgard NB.

Expert Opin Investig Drugs. 2009 Aug;18(8):1219-30. doi: 10.1517/13543780903136708. Review.

PMID:
19604122
13.

A Safety Evaluation of Cangrelor in Patients Undergoing PCI.

Franchi F, Rollini F, Park Y, Angiolillo DJ.

Expert Opin Drug Saf. 2016;15(2):275-85. doi: 10.1517/14740338.2016.1133585. Epub 2016 Jan 9. Review.

PMID:
26680584
14.

Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists.

Schneider DJ.

Coron Artery Dis. 2016 Jan;27(1):65-9. doi: 10.1097/MCA.0000000000000311. Review.

PMID:
26444255
15.

Pharmacodynamic effects during the transition between cangrelor and prasugrel.

Schneider DJ, Seecheran N, Raza SS, Keating FK, Gogo P.

Coron Artery Dis. 2015 Jan;26(1):42-8. doi: 10.1097/MCA.0000000000000158.

PMID:
25089928
16.

Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect.

Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS.

Thromb Res. 2008;121(4):527-34. Epub 2007 Jul 13.

PMID:
17631948
17.

Cangrelor for treatment of coronary thrombosis.

Fugate SE, Cudd LA.

Ann Pharmacother. 2006 May;40(5):925-30. Epub 2006 Apr 4. Review.

PMID:
16595568
18.

Cangrelor for treatment of arterial thrombosis.

Walsh JA 3rd, Price MJ.

Expert Opin Pharmacother. 2014 Mar;15(4):565-72. doi: 10.1517/14656566.2014.882319. Epub 2014 Jan 30. Review.

PMID:
24479981
19.

Cangrelor: a review on pharmacology and clinical trial development.

Franchi F, Rollini F, Muñiz-Lozano A, Cho JR, Angiolillo DJ.

Expert Rev Cardiovasc Ther. 2013 Oct;11(10):1279-91. doi: 10.1586/14779072.2013.837701. Review.

PMID:
24138516
20.

Current status of data on cangrelor.

Qamar A, Bhatt DL.

Pharmacol Ther. 2016 Mar;159:102-9. doi: 10.1016/j.pharmthera.2016.01.004. Epub 2016 Jan 21. Review.

PMID:
26802900

Supplemental Content

Support Center